Cohen Cynthia B, Cohen Peter J
Kennedy Institute of Ethics, Georgetown University, Washington, DC, USA.
Kennedy Inst Ethics J. 2010 Mar;20(1):27-49. doi: 10.1353/ken.0.0305.
Persons with serious and disabling medical conditions have traveled abroad in search of stem cell treatments in recent years. However, weak or nonexistent oversight systems in some countries provide insufficient patient protections against unproven stem cell treatments, raising concerns about exposure to harm and exploitation. The present article, the first of two, describes and analyzes stem cell tourism in Russia and India and addresses several scientific/medical, ethical, and policy issues raised by the provision of unproven stem cell-based treatments within them. The distinction between treatment based on proven clinical research and "innovative treatment" is addressed and the authors conclude that the innovations at issue constitute neither. Regulatory measures need to be developed or strengthened in accord with internationally accepted standards in such countries to protect those seeking stem cell treatments.
近年来,患有严重致残性疾病的人前往国外寻求干细胞治疗。然而,一些国家的监管体系薄弱或不存在,无法为患者提供足够的保护,使其免受未经证实的干细胞治疗的影响,这引发了人们对伤害和剥削风险的担忧。本文是系列文章中的第一篇,描述并分析了俄罗斯和印度的干细胞旅游现象,并探讨了在这两个国家提供未经证实的干细胞治疗所引发的一些科学/医学、伦理和政策问题。文章讨论了基于已证实的临床研究的治疗与“创新治疗”之间的区别,作者得出结论,所讨论的创新疗法均不属于这两者。这些国家需要根据国际公认的标准制定或加强监管措施,以保护寻求干细胞治疗的人。